Cell Therapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Cell Therapy stocks.

Cell Therapy Stocks Recent News

Date Stock Title
Nov 1 LSTA Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know
Nov 1 ALLO Earnings Preview: ANI Pharmaceuticals (ANIP) Q3 Earnings Expected to Decline
Nov 1 COYA Coya Therapeutics names Arun Swaminathan as CEO
Nov 1 COYA Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
Oct 31 IOVA Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024
Oct 31 COYA Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
Oct 31 ALLO Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know
Oct 31 LSTA Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
Oct 30 CARM Carisma Therapeutics Announces Changes to its Board of Directors
Oct 30 ALVR Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
Oct 30 ALLO Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Oct 30 COYA Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
Oct 29 COYA Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
Oct 29 COYA Coya stock tumbles 23% on mixed results from Alzheimer's study
Oct 29 ALLO Allogene receives FDA RMAT designation for its metastatic renal cell carcinoma treatment
Oct 29 ALLO We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Oct 29 ALLO Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Oct 29 COYA Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
Oct 28 LSTA Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Oct 28 COYA Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
Cell Therapy

Cell therapy (also called cellular therapy or cytotherapy) is therapy in which cellular material is injected into a patient; this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy.
Cell therapy originated in the nineteenth century when scientists experimented by injecting animal material in an attempt to prevent and treat illness. Although such attempts produced no positive benefit, further research found in the mid twentieth century that human cells could be used to help prevent the human body rejecting transplanted organs, leading in time to successful bone marrow transplantation.Today two distinct categories of cell therapy are recognized.The first category is cell therapy in mainstream medicine. This is the subject of intense research and the basis of potential therapeutic benefit. Such research can be controversial when it involves human embryonic material.
The second category is in alternative medicine, and perpetuates the practice of injecting animal materials in an attempt to cure disease. This practice, according to the American Cancer Society, is not backed by any medical evidence of effectiveness, and can have deadly consequences.

Browse All Tags